VERU Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -128.15% compared to Veru, Inc.'s net margin of --. Veru, Inc.'s return on equity of -95.96% beat CEL-SCI Corp.'s return on equity of -266.61%.

Veru, Inc. has a consensus price target of $19.75, signalling upside risk potential of 693.17%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that Veru, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Veru, Inc. is more attractive than CEL-SCI Corp..

Veru, Inc. has a beta of -1.007, which suggesting that the stock is 200.726% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Veru, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Veru, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Veru, Inc.'s net income of -$7.3M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Veru, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru, Inc. is 42.44x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -128.15% compared to Veru, Inc.'s net margin of -953.4%. Veru, Inc.'s return on equity of -95.96% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Veru, Inc. has a consensus price target of $19.75, signalling upside risk potential of 693.17%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that IGC Pharma, Inc. has higher upside potential than Veru, Inc., analysts believe IGC Pharma, Inc. is more attractive than Veru, Inc..

Veru, Inc. has a beta of -1.007, which suggesting that the stock is 200.726% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Veru, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Veru, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Veru, Inc.'s net income of -$7.3M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Veru, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru, Inc. is 42.44x versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -128.15% compared to Veru, Inc.'s net margin of -255.85%. Veru, Inc.'s return on equity of -95.96% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Veru, Inc. has a consensus price target of $19.75, signalling upside risk potential of 693.17%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Veru, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Veru, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Veru, Inc. has a beta of -1.007, which suggesting that the stock is 200.726% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Veru, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Veru, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Veru, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Veru, Inc.'s net income of -$7.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Veru, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru, Inc. is 42.44x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Onconetix, Inc. has a net margin of -128.15% compared to Veru, Inc.'s net margin of -2892.23%. Veru, Inc.'s return on equity of -95.96% beat Onconetix, Inc.'s return on equity of -377.25%.

Veru, Inc. has a consensus price target of $19.75, signalling upside risk potential of 693.17%. On the other hand Onconetix, Inc. has an analysts' consensus of -- which suggests that it could grow by 1188250.11%. Given that Onconetix, Inc. has higher upside potential than Veru, Inc., analysts believe Onconetix, Inc. is more attractive than Veru, Inc..

Veru, Inc. has a beta of -1.007, which suggesting that the stock is 200.726% less volatile than S&P 500. In comparison Onconetix, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Veru, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Onconetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru, Inc. pays -- of its earnings as a dividend. Onconetix, Inc. pays out -- of its earnings as a dividend.

Veru, Inc. quarterly revenues are --, which are smaller than Onconetix, Inc. quarterly revenues of $303.7K. Veru, Inc.'s net income of -$7.3M is higher than Onconetix, Inc.'s net income of -$8.8M. Notably, Veru, Inc.'s price-to-earnings ratio is -- while Onconetix, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru, Inc. is 42.44x versus 1.22x for Onconetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.